Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-β1-Smad2/3 and JNK signalling pathways. (1st January 2020)
- Record Type:
- Journal Article
- Title:
- Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-β1-Smad2/3 and JNK signalling pathways. (1st January 2020)
- Main Title:
- Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-β1-Smad2/3 and JNK signalling pathways
- Authors:
- Zhang, Jinjin
Chen, Xiaoqing
Chen, Hongbin
Li, Rongrong
Xu, Pan
Lv, Changjun
Liu, Bo
Song, Xiaodong - Abstract:
- Abstract: Context: Pulmonary fibrosis (PF) is a highly heterogeneous and lethal pathological process having no effective drug. Engeletin exerts multiple biological activities including anti-inflammatory and lung repair. Whether engeletin has therapeutic effects on PF remains unclear. Objective: Examining effect and mechanism of engeletin on PF in vivo and in vitro. Materials and methods: L929 cells (1 × 10 6 /well) were treated with TGF-β1 (5 ng/mL). Sixty male C57BL/6 mice were divided into three groups and given saline or single intratracheal instillation bleomycin (5 mg/kg) or both bleomycin and intraperitoneally injected engeletin (25 mg/kg). Results: Histological staining showed engeletin inhibited myofibrobasts activation and improved alveolar structure. Engeletin elevated forced vital capacity from 12 induced by bleomycin to 17. CCK-8 assay reported IC50 value of engeletin was 270 μg/mL. Real-time cellular analysis showed engeletin reduced proliferation and migration of myofibroblasts by 2.5- and 2-fold. Engeletin blocked α-SMA, vimentin, and collagen expression. RNA sequencing revealed PERK-ATF4 signalling pathway relating to ER stress involved in anti-fibrotic function of engeletin. Engeletin reduced ATF4, CHOP and BIP expression. Chemical inhibitors of smad2/3- (SB431542) and JNK- (SP600125) signalling pathways blocked expression of long noncoding RNA (lncRNA) – lnc949. Engeletin inhibited phosphorylation of smad2/3 and JNK leading to lower level of lnc949.Abstract: Context: Pulmonary fibrosis (PF) is a highly heterogeneous and lethal pathological process having no effective drug. Engeletin exerts multiple biological activities including anti-inflammatory and lung repair. Whether engeletin has therapeutic effects on PF remains unclear. Objective: Examining effect and mechanism of engeletin on PF in vivo and in vitro. Materials and methods: L929 cells (1 × 10 6 /well) were treated with TGF-β1 (5 ng/mL). Sixty male C57BL/6 mice were divided into three groups and given saline or single intratracheal instillation bleomycin (5 mg/kg) or both bleomycin and intraperitoneally injected engeletin (25 mg/kg). Results: Histological staining showed engeletin inhibited myofibrobasts activation and improved alveolar structure. Engeletin elevated forced vital capacity from 12 induced by bleomycin to 17. CCK-8 assay reported IC50 value of engeletin was 270 μg/mL. Real-time cellular analysis showed engeletin reduced proliferation and migration of myofibroblasts by 2.5- and 2-fold. Engeletin blocked α-SMA, vimentin, and collagen expression. RNA sequencing revealed PERK-ATF4 signalling pathway relating to ER stress involved in anti-fibrotic function of engeletin. Engeletin reduced ATF4, CHOP and BIP expression. Chemical inhibitors of smad2/3- (SB431542) and JNK- (SP600125) signalling pathways blocked expression of long noncoding RNA (lncRNA) – lnc949. Engeletin inhibited phosphorylation of smad2/3 and JNK leading to lower level of lnc949. Knockdown lnc949 inhibited ATF4, CHOP and BIP expression. Conclusions: We reported gene expression profiling of engeletin through RNA-seq; and identified lnc949-mediated TGF-β1-Smad2/3 and JNK were upstream signalling pathways of ER stress induced by engeletin. Our results showed engeletin remedies pulmonary fibrogenesis and may be a new drug candidate. … (more)
- Is Part Of:
- Pharmaceutical biology. Volume 58:Number 1(2020)
- Journal:
- Pharmaceutical biology
- Issue:
- Volume 58:Number 1(2020)
- Issue Display:
- Volume 58, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 58
- Issue:
- 1
- Issue Sort Value:
- 2020-0058-0001-0000
- Page Start:
- 1114
- Page End:
- 1123
- Publication Date:
- 2020-01-01
- Subjects:
- PF -- lncRNA -- RNA sequence -- PERK-ATF4 signalling pathway -- ER stress
Pharmacognosy -- Periodicals
Materia medica, Vegetable -- Periodicals
615.321 - Journal URLs:
- http://www.tandfonline.com/toc/iphb20/current ↗
http://informahealthcare.com/journal/phb ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/13880209.2020.1834590 ↗
- Languages:
- English
- ISSNs:
- 1388-0209
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6442.767000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22163.xml